prof. dr. M.C. (Monique) Minnema

prof. dr. M.C. (Monique) Minnema

Full Professor
prof. dr. M.C. (Monique) Minnema
  • Department of Hematology



Prof Dr Monique Minnema was trained as internist and hematologist at Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the department of hematology, UMC Utrecht and was appointed full professor in 2019. She is specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasis  like Multiple Myeloma and AL amyloidosis, and Waldenstrom Macroglobulinemia. Prof Minnema is author on several national and internatonial quidelines on the diagnosis and treatment of these diseases.
She is head supervisor of the hematology clinical research team, the hematology biobank and the European expertise reference network (ERN) malignant hematology of the UMC Utrecht. Her main focus of clinical research is the development of novel therapies (both cellular and drug) developments for plasma cell dyscrasias 

Prof Dr Minnema is an active member of the HOVON working parties for Multiple
Myeloma, Lymphoma, IEC and the vice president of the Lunenburg Lymphoma consortium (LLPC) for phase I/II studies. Examples of her work are the HOVON 104 trial for
patients with AL amyloidosis first line treatment, the clinical studies with
the monoclonal antibody Daratumumab in relapsed Multiple Myeloma and newly diagnosed AL amyloidosis and anti CD19 CAR T cells in relapsed Lymphoma.
Her translational research focuses on 3D models to predict response to therapy and the use of combined immunotherapy for relapsed multiple myeloma.

She was a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016, and is co initiator of the yearly Immune Effector Cell and the Systemic Amyloidosis symposia. 

Side Activities


  • NIV
  • NVvH
  • ASH
  • EHA

Board activities:

  • 2006 onwards: member HOVON working party multiple myeloma, lymphoma, LLPC and Immune Effector Cell (IEC)
  • 2014 onwards: board member Nederlandse Vereniging van Hematologie
  • 2019 onwards: program committee yearly Symposium on Systemic Amyloidosis and Symposium IEC
  • 2019 onwards: Women in Lymphoma steering committee (international)
  • 2021-2022: lid ZonMw beoordelingscommissie
  • 2022 onwards: lid KWF beoordelingscommissie Ontwikkeling en Implementatie
  • May – Nov 2022: lid structuurcommissie van de leerstoel ‘Antistoftherapie’ 
  • May 2022 onwards: bestuurslid HOVON Myeloom WG 
  • August 2022 onwards: member MPE’s Medical Advisory Committee
  • Sept 2022 onwards: member steering committee Aquarius trial
  • Sept 2022 onwards: member IWMF Scientific Advisory Sub-Committee on the Waldenstrom’s Macroglobulinemia (WM) Global Awareness Building Initiative
  • Oct 2022: Member International Myeloma Working Group 

Conflicts of interest:

  • 2022: paid to institution, consultancy Jansen Cilag, BMS, GSK. speakers bureau Binding Site
  • 2021: paid to institution, speakers bureau Medscape, paid to institution consultancy Jansen Cilag
  • 2020: paid to institution, speakers bureau Celgene, paid to institution consultancy Jansen Cilag
  • 2019: paid to institution, speakers bureau Gilead, paid to institution consultancy Alnylam, paid to person; Hospitality Celgene
  • 2018: paid to institution, speakers bureau Roche, Gilead, Celgene, paid to institution consultancy Takeda, Jansen Cilag, paid to person; Hospitality Celgene

Stichting Transparantieregister Zorg - Home, BIG 59043578201

Research Output (161)

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001):a multicentre, multicohort, open-label, phase 1/2 trial

Lonial Sagar, Popat Rakesh, Hulin Cyrille, Jagannath Sundar, Oriol Albert, Richardson Paul G, Facon Thierry, Weisel Katja, Larsen Jeremy T, Minnema Monique C, Abdallah Al-Ola, Badros Ashraf Z, Knop Stefan, Stadtmauer Edward A, Cheng Yiming, Amatangelo Michael, Chen Min, Nguyen Tuong Vi, Amin Alpesh, Peluso Teresa, van de Donk Niels W C J 6 Oct 2022, In: Lancet haematology. 9 , p. e822-e832

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Sonneveld Pieter, Zweegman Sonja, Cavo Michele, Nasserinejad Kazem, Broijl Annemiek, Troia Rosella, Pour Ludek, Croockewit Sandra, Corradini Paolo, Patriarca Francesca, Wu Kalung, Droogendijk Jolanda, Bos Gerard, Hajek Roman, Teresa Petrucci Maria, Ypma Paula, Zojer Nicholas, Minnema Monique C, Boccadoro Mario Oct 2022, In: HemaSphere. 6 , p. 1-8

Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline

Amaador Karima, Kersten Marie José, Minnema Monique C, Vos Josephine M I Jul 2022, In: HemaSphere. 6 , p. 1-7

IgM monoclonal gammopathies of clinical significance:diagnosis and management

Khwaja Jahanzaib, D'Sa Shirley, Minnema Monique C, Kersten Marie José, Wechalekar Ashutosh, Vos Josephine M 30 Jun 2022, In: Haematologica. 107 , p. 2037-2050 14 p.

Central Nervous System Progression in Primary Vitreoretinal Lymphoma with Bilateral and Unilateral Involvement:A Systematic Review and Meta-Analysis

van Rooij Josephus L M, Tokarska Klaudia A, Ten Dam-van Loon Ninette H, Wessels Peter H, Seute Tatjana, Minnema Monique C, Snijders Tom J 16 Jun 2022, In: Cancers. 14 , p. 1-14

Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab:results from the ANDROMEDA study

Sanchorawala Vaishali, Palladini Giovanni, Minnema Monique C, Jaccard Arnaud, Lee Hans C, Gibbs Simon, Mollee Peter, Venner Christopher, Lu Jin, Schönland Stefan, Gatt Moshe, Suzuki Kenshi, Kim Kihyun, Cibeira M Teresa, Beksac Meral, Libby Edward, Valent Jason, Hungria Vania, Wong Sandy W, Rosenzweig Michael, Bumma Naresh, Chauveau Dominique, Gries Katharine S, Fastenau John, Tran Nam Phuong, Qin Xiang, Vasey Sandra Y, Weiss Brendan M, Vermeulen Jessica, Ho Kai Fai, Merlini Giampaolo, Comenzo Raymond L, Kastritis Efstathios, Wechalekar Ashutosh D 16 Mar 2022, In: American Journal of Hematology. 97 , p. 719-730 12 p.

Increased mortality risk in multiple-myeloma patients with subsequent malignancies:a population-based study in the Netherlands

Brink Mirian, Minnema Monique C, Visser Otto, Levin Mark-David, Posthuma Eduardus F M Ward, Broijl Annemiek, Sonneveld Pieter, van der Klift Marjolein, Roeloffzen Wilfried W H, Westerman Matthijs, van Rooijen Cleo R, Geerts Paul A F, Zweegman Sonja, van de Donk Niels W C J, Dinmohamed Avinash G 15 Mar 2022, In: Blood cancer journal. 12 , p. 1-4

Evaluation of the cardiac amyloidosis clinical pathway implementation:a real-world experience

Brons Maaike, Muller Steven A, Rutten Frans H, van der Meer Manon G, Vrancken Alexander F J E, Minnema Monique C, Baas Annette F, Asselbergs Folkert W, Oerlemans Marish I F J Mar 2022, In: European heart journal open. 2 , p. 1-9

Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy

Amaador Karima, Wieske Luuk, Koel-Simmelink Marleen J A, Kamp A, Jongerius Ilse, de Heer Koen, Teunissen Charlotte E, Minnema Monique C, Notermans Nicolette C, Eftimov Filip, Kersten Marie José, Vos Josephine M I 14 Feb 2022, In: Journal of Neurology. 269 , p. 3700-3705 6 p.

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma:A Prospective Study Within the Nationwide Netherlands Cancer Registry

Wester Ruth, Dinmohamed Avinash G, van der Holt Bronno, Zweegman Sonja, Minnema Monique, Croockewit Sandra, Levin Mark-David, Libourel Eduard, de Waal Esther, Sonneveld Pieter, Cornelissen Jan, Blijlevens Nicole, Broijl Annemiek Feb 2022, In: HemaSphere. 6 , p. 1-6

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.



Praktisch maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet